First Line gastroeSOphageal metastatiC canceR primAry and disTant (if Oligometastatic) lEsions-directed Radiotherapy, a Multicentric, Phase III, Randomized Controlled Trial

NCT06922279 · tracked via the Priya Life Science Italy tracker

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase

Not applicable

Started

2024-11-30

Last updated

2025-05-11

Condition(s) studied

Gastroesophageal Cancer (GC)

Investigational drug(s) / intervention(s)

Radiation Therapy + standard sistemic therapy (chemoteraphy)Standard systemic therapy (chemotherapy)

Radiation Therapy + standard sistemic therapy (chemoteraphy): Standard systemic therapy (chemotherapy treatment with carboplatin-taxol or with drugs that the oncologist considers most useful) + combination of RT on the primary gastroesophageal Gross Tumor Volume (GTV) + SBRT on each of the distal lesions for oligometastatic or limited metastatic spread patients (to be delivered prior to initiation of systemic therapy).

Standard systemic therapy (chemotherapy): The patients will go to standard therapy (chemotherapy treatment with carboplatin-taxol or with drugs that the oncologist that the oncologist considers most useful.) without RT/SBRT combination

Study summary

The aim of the study is to evaluate the efficacy of radiotherapy on the primary site of gastroesophageal cancer and extracranial stereotactic radiotherapy on metastases before the use of standard systemic therapy, in cases of limited disease burden (in the experimental group), compared to the standard group, which does not receive radiotherapy. This prospective, multicenter, randomized trial aims to evaluate the efficacy of the unconventional approach versus the conventional one in increasing the percentage of asymptomatic patients due to the direct effect of the primary tumor or metastases. "Randomized" means that the assignment to one of the treatment groups mentioned above will be random, not influenced by the physician or the patient's condition. Therefore, your participation in either of the two treatments under study will be assigned randomly and not predetermined. This randomness is crucial for a proper analysis of the results at the end of the study, which will help clarify whether there are differences between the two proposed treatments. This also means that you may not receive direct benefits from participating in this study, as it is a research study.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Patients diagnosed with gastroesophageal cancer (i.e.: esophagus, gastroesophageal junction, stomach), for both major squamous cell (SCC) and adenocarcinomatous (ADK) histologies, metastatic, candidate for first-line standard systemic treatment; either newly diagnosed in metastatic stage or first progression to metastasis. * Obtaining informed consent. * Patients \>18 years of age * ECOG 0-2 * Performance of imaging (CT with mdc, MRI with mdc, CT-PET with appropriate tracer) adequate for baseline local and systemic staging and likely to be similarly repeatable at 6 and 12 months after randomization * Confirmation at the time of randomization, by the Radiation Therapy Center, that all potentially planned treatments can be performed for the patient (if enrolled in experimental arm) within a maximum of 25 days total before referral to the Medical Oncology Center for systemic therapy Exclusion Criteria: * Metastatic picture of line following the first * Technical or organizational inability to the eventual deadline for radiation treatments within 25 days of randomization * Inability to express independent consent to treatments * Pregnancy * Patient in hospice or with prognosis \< 6 months * Predicted unavailability for follow-up at 6 months * Absence of adequate or likely non-repeatable pretreatment imaging study at 6 and 12 months * Previous radiation therapy * Previous radiometabolic therapy * Inability to maintain treatment position for SBRT * Symptomatic emergent or other presentation precluding study development as planned (e.g., epidural compression of the spinal cord or cauda equina) * Previous chemotherapy, immunotherapy or target therapy

Primary outcome measure(s)

Disappearance of symptoms — From the week after the treatment up to 12 months after
Percentage difference in the rate of patients with symptom (from primary tumor or metastasis) developed within the first 6 months.

Trial sites (1)

Facility	City	Region	Status
Policlinico Universitario Agostino Gemelli IRCSS	Rome	RM

More Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials in Italy

The Management of Asymptomatic Carotid Stenosis Recruiting

Modular Neurological Examination for Early Risk Detection Active, not recruiting

Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. Recruiting

BRCA Mutation Carriers' Platform a Multicenter Study Recruiting

Superior Cervical Ganglion in Parkinson's Disease Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06922279 on ClinicalTrials.gov ↗ ← All trials in Italy